Roche bolsters MS blockbuster Ocrevus with new long-term disability data
admin 10th October 2018 Uncategorised 0Ocrevus was already the most successful drug launch in Roche’s 122-year history, having hit blockbuster status this summer. Now Roche is rolling out new five-year data from a pivotal trial that could ratchet up the enthusiasm for the product—and sway payers that may be hesitant to pay for it.
More: Roche bolsters MS blockbuster Ocrevus with new long-term disability data
Source: fierce